Regulation made simple thanks to Matrix Mind AI chatbot

Ask any complex question about regulation & standards in EU and the USA and get an accurate answer.

Trusted by 300+ SxMD & Medical Device Companies

Core Matrix Mind Features

AI isn’t the future of regulatory affairs — it’s the now. Empower Regulatory & Quality teams with AI-driven guidance, automation, and compliance intelligence.

Instant Precise GuidanceAnswers to complex regulatory questions — with citations from FDA, EU MDR, and more. Stay compliant, even as the rules evolve.

Smart Document AssistantValidate, and optimise regulatory documents like DHFs, technical files, and risk assessments using contextual AI. Ensure completeness and alignment with current standards.

Remove the guessworkSurface relevant regulatory guidance, SOPs, and templates — intelligently tailored to your role and current task. Matrix Mind knows what matters, when it matters.

Secure. Scalable. Searchless.No more clicking through folders or searching with vague keywords. Just ask, and get structured, reference-backed responses. All data stays securely within your environment.

Curated Compliance ContentPowered by private AI models trained on a well-curated internal repository built by Matrix regulatory experts.

Compliance Workflow NavigatorContext-aware prompts guide users through complex regulatory and quality procedures.

Matrix Mind vs. ChatGPT: A Comparative Overview

	Matrix Mind	ChatGPT
Domain-Specific Accuracy	✅ 98%	55%^*
Data security	✅ Zero data retention	Partial control over your data
Updated ground truth	✅ Curated up-to-date references	Relative to model release date
Traceability of answers	✅ Citations to exact source document	Broad references to sources
Industry specific	✅ Tailored to Medtech need	General purpose usage
Risk of incorrect answers	✅ Reduced by precise inputs grounding	Higher on specialized areas
Controlled vocabulary	✅ Use of consistent, formal, and aligned language with regulatory expectations	Uncontrolled tone and varying output formatting

^* based on a survey with 50 regulatory affairs specialists